Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis

Ilaria Bertoldi1
Roberto Caporali2

1Medical Department, Pfizer Italy, Rome, Italy; 2Department of Clinical Sciences and Community Health, University of Milan and ASST Pini-CTO Hospital, Milan, Italy

Abstract: Tofacitinib is an oral Janus kinase (JAK) inhibitor indicated for the treatment of rheumatoid arthritis (RA). The efficacy and safety/tolerability of tofacitinib have been extensively evaluated as monotherapy and combination therapy in multiple, randomised, multicentre studies in patients with RA. Tofacitinib as monotherapy (as first- and second-line treatment) or as combination with methotrexate (MTX) or other csDMARDs as second- and third-line treatment is effective and generally well tolerated in patients with RA. This article focuses on recent real-world evidence investigating the effectiveness, treatment persistence and safety/tolerability of tofacitinib in patients with RA. With this purpose, a literature review was conducted from April 2018 up to October 2020 for the effectiveness, persistence and safety of tofacitinib for the treatment of RA, primarily focusing on real-world studies. These retrospective and prospective and observational studies demonstrate the effectiveness of tofacitinib, thus supporting pivotal data from the clinical trial programme. Treatment persistence was generally comparable to that of biologic disease-modifying anti-rheumatic drugs. Safety findings in these observational studies were consistent with the known safety profile of the approved dose of 5 mg twice daily.

Keywords: rheumatoid arthritis, real-world, effectiveness, persistence

Introduction

Recent EULAR recommendations for the management of rheumatoid arthritis (RA) state that following failure of 1 or more conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) and in the presence of at least one poor prognostic factor, a Janus kinase (JAK) inhibitor or a biological DMARD (bDMARD) should be started.1 Tofacitinib is an oral JAK inhibitor for the treatment of RA. In cellular settings where JAKs signal in pairs, tofacitinib preferentially inhibits signalling by heterodimeric receptors associated with JAK1 and/or JAK3 and has functional selectivity over JAK2.2,3

The efficacy and safety/tolerability of tofacitinib have been extensively evaluated as monotherapy and combination therapy in multiple 6- to 24-month, randomised, double-blind, multicentre, Phase 3 or 3b/4 Oral Rheumatoid Arthritis (ORAL) studies in patients with RA. The findings from these controlled trials demonstrate that tofacitinib monotherapy (as first- and second-line treatment) and in combination with methotrexate (MTX) or other csDMARDs as second- and third-line treatment is effective and generally well tolerated in patients with RA.4–11

The open-label ORAL Sequel long-term extension study presented efficacy data for up to 8 years and safety data for up to 9.5 years on 4481 RA patients and a total tofacitinib exposure of 16,291 patient-years.12 Tofacitinib maintained American
College of Rheumatology-20% (ACR20), −50% (ACR50) and −70% (ACR70) response rates between months 1 and 96, and efficacy was generally similar for 5 mg twice daily (BID) (months 1 to 96) and 10 mg BID (months 1 to 72). Tofacitinib (5 mg and 10 mg BID) reduced mean erythrocyte sedimentation rate (ESR)-based disease activity score assessed in 28 joints (DAS28-ESR) and improved mean Health Assessment Questionnaire Disability Index (HAQ-DI) scores at month 1; both DAS28-ESR and HAQ-DI scores remained stable during 96 months of treatment. Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI)-defined remission were obtained in about one-third of patients at month 96.

Tofacitinib administered as monotherapy or combination therapy showed a consistent safety profile.12 The incidence rate for AEs leading to discontinuation was 6.8 patients per 100 patient-years. For all-cause AEs of special interest, the incidence rate was 3.4 per 100 patient-years for herpes zoster, and was lower for serious infections (2.4/100 patient-years), malignancies excluding non-melanoma skin cancer (NMSC; 0.8/100 patient-years), major adverse cardiovascular events (0.4/100 patient-years) and all-cause mortality (0.3/100 patient-years). Most all-cause AEs for tofacitinib were mild (59%) or moderate (36%) in severity, and proportions of mild and moderate all-cause AEs were similar for patients receiving tofacitinib 5 mg or 10 mg BID.

Observational studies and data collections from registries provide real-world evidence of therapies and complement randomised controlled trials (RCTs) as they provide invaluable information about routine clinical practice.13–15 This review focuses on recent real-world evidence investigating the effectiveness, treatment persistence and safety/tolerability of tofacitinib in patients with RA, available since the review by Caporali & Zavaglia in 2019.16

**Methods**

For the purposes of this narrative review, PubMed was searched on 23rd October 2020 using the search terms “tofacitinib” and “rheumatoid arthritis” and limited to articles published from April 2018 up to October 2020. A total of 290 articles were assessed for relevance, focusing on real-world studies; long-term extension and economic studies were also found and evaluated if pertinent. Abstracts from ACR, European League Against Rheumatism (EULAR), and Asia Pacific League of Associations for Rheumatology (APLAR) meetings from 2018 to 2020 were also searched, since these often present the first reports and most up-to-date experience with drug therapy. The publications were subgrouped by those evaluating effectiveness and/or persistence and/or safety.

**Results**

**Effectiveness and/or Persistence**

Two real-world studies which analysed claims database or registry data reported only effectiveness outcomes.17,18 Interrogation of US MarketScan® databases over a three-year period (2011–2014) showed similar effectiveness rates for tofacitinib and non-TNF biologics. In a retrospective cohort analysis of MarketScan® databases involving 21,832 RA patients (0.8% receiving tofacitinib), six strict criteria were used to define effective therapy.17 After one year, therapeutic effectiveness was 15.4% for tofacitinib, compared to 18.6% for TNFi, 19.8% for non-TNFi biologics and 11.1% for csDMARDs. Analysis of the US Coronra RA registry compared outcomes in patient cohorts receiving TNFi (n = 8014) or tofacitinib (n = 558) with/without MTX.18 Effectiveness was assessed by CDAI-based low disease activity (LDA)/remission and modified ACR20 response rate. Tofacitinib as monotherapy or in combination achieved an efficacy similar to TNFi in combination with MTX in the third/fourth line, while association with MTX improved efficacy of TNFi in the second/third line.

Fourteen studies reported on the effectiveness and/or persistence of tofacitinib (Table 1). A retrospective study of US insurance claims databases compared patients who switched from adalimumab or etanercept to tofacitinib (n = 549) with those switching from adalimumab to etanercept or conversely from etanercept to adalimumab (n = 191).19 Patients who switched from adalimumab to tofacitinib had significantly higher persistence (defined as persistence without a ≥60-day gap in index therapy or switch) and longer duration of therapy.

Thanks to the real-world collection in the US, information was obtained about two formulations of tofacitinib—modified-release (MR) 11 mg daily (QD) and immediate-release (IR) 5 mg twice daily (BID) – which were compared for effectiveness and adherence of patients initiating either product following interrogation of US claims databases (n = 1057) and the Coronra US RA Registry (n = 450)20 (in 2016, in US, an extended-release dose of tofacitinib 11 mg once daily was approved). Assessed using clinical disease activity after 6 months of treatment, effectiveness was similar between the two formulations. Adherence was significantly higher with
| Study          | Data Source                                                                 | n                          | Design and Patients                                                                 | Objectives                                                                                      | Tofacitinib Treatment | Main Findings                                                                                     | Treatment Persistence, Discontinuation and Adherence |
|---------------|-----------------------------------------------------------------------------|----------------------------|----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|-----------------------|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| Harnett et al 2019<sup>19</sup> | US-based IBM® MarketScan<sup>®</sup> Commercial and Medicare Supplemental insurance claims databases (January 2014 – September 2016) | 740: switched from ADA or ETN to TOF (n=549); cycled between ADA and ETN (n=191) | Retrospective cohort study                                                                 | Impact of TNFi cycling with ADA & ETN vs switching to TOF | NA                                  | Patients switching from ADA/ETN to TOF had higher persistence, effectiveness, and significantly lower change in RA-related costs vs patients switching from ADA to ETN | Persistence rates: switching from ADA to TOF vs ADA to ETN, 50.5% vs 36.7% (p=0.03); from ETN to TOF vs ETN to ADA, 45.8% vs 38.4% (p=0.19). |
| Cohen et al 2020<sup>20</sup> | US IBM® MarketScan<sup>®</sup> Commercial and Medicare Supplemental insurance claims databases (March 2016 – October 2018); Corrona US RA Registry (February 2016 – August 2019) | US claims databases (n=1057); Corrona US RA Registry (n=450: MR 11 mg QD, n=297; IR 5 mg BID, n=153) | Retrospective, non-interventional cohort studies | Compare real-world adherence and effectiveness between patients initiating MR and IR formulations | TOF modified-release (MR) 11 mg QD vs immediate-release (IR) 5 mg BID | Effectiveness of TOF MR 11 mg QD was non-inferior to TOF IR 5 mg BID, assessed using two CDAI-based outcomes. | TOF MR 11 mg QD improved adherence. Adherence in TOF MR vs IR initiators: 12-month ≥ 0.8 PDC: 48.2% vs 37.7% (p=0.001). 12-month ≥ 0.8 MPR: 80.1% vs 69.9% (p=0.0002). 12-month mean duration of treatment for TOF MR vs IR: 243.4 vs 235.7 days (p=0.36) |
| Fisher et al 2020<sup>21</sup> | Canadian IBM MarketScan Research Databases (November 2012 – December 2016) | New TOF users (n=1031); new bDMARD users (n=17,803) | Retrospective cohort study | Compare medication persistence of TOF vs injectable bDMARDs | New TOF users had shorter persistence compared with new bDMARD patients | Median persistence: TOF, 0.81 yr; bDMARDs, 1.02 yr. HR for discontinuation of TOF vs bDMARDs = 1.14 (95% CI: 1.05–1.25) | (Continued) |
Table 1 (Continued).

| Study                        | Data Source                                                                 | n             | Design and Patients                          | Objectives                                                                                         | Tofacitinib Treatment | Main Findings                                                                 | Treatment Persistence, Discontinuation and Adherence |
|------------------------------|----------------------------------------------------------------------------|---------------|-----------------------------------------------|----------------------------------------------------------------------------------------------------|-----------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| Movahedi et al 2020          | Ontario Best Practices Research Initiative (OBRI) provincial registry, Canada | 565 patients  | Retrospective cohort study                    | Discontinuation rates of TOF in comparison with TNFi, with/without concurrent MTX                  | NA                    | TOF retention in patients with/without MTX was similar                          | Discontinuation rates: TOF, 36% (n=75); TNFi, 29%  (n=103)                                           |
| Pope et al 2020              | Canadian eXel programme (2014–2017)                                         | 4276 patients | Post hoc observational aggregated study        | Describe characteristics, treatment patterns and persistence in RA patients treated with TOF       | TOF 5mg BID, n=4092 (95.7%); 5 mg QD, n=184 (4.3%) | Increased use of TOF since 2014, especially among bDMARD-naïve/1-prior-bDMARD patients. Median persistence was ~2 years. Likelihood of persistence increased for bDMARD-naïve (vs bDMARD-experienced) patients and those aged ≥56 (vs ≤45) years. | Discontinuation rate for TOF (n=3678), 33.3%: due to ineffectiveness (35.7%), AEs (26.9%). Persistence: at 1 yr, 62.7%; at 2 yr, 49.6% |
| Tamura et al 2018             | Post-marketing surveillance in Japan                                        | 3929          | Post-marketing interim analysis (first 6-month observation period) of 3-year follow-up | Rates of SAEs, malignancies, and deaths in Japanese RA patients receiving TOF [See Safety section below] | See Safety section (Table 2) | 6-month discontinuation rate, 22.7%: due to AEs (8.9%), ineffectiveness (8.5%). |
| Mori & Ueki 2019             | Japanese single centre: NHO Kumamoto Saishunsou National Hospital (August 15, 2013 – August 15, 2017) | 100           | Prospective observational study               | Compare outcomes of dose reduction, withdrawal, and restart of TOF in RA                          | TOF 5 mg, BID for 1 year | At 1-year: remission (53%), LDA (15%). Incidence rates (95% CI) of disease flare: after withdrawal, 0.73 per person-year (0.43–1.22); after dose reduction, 0.44 (0.25–0.77); during continuation 0.04 (0.01–0.27). | 1-year discontinuation rate 32%: due to ineffectiveness (24%), AEs (4%), patient preference (4%). |
| Authors | Registry | Patients and Courses | Methods | Study Objective | Results |
|---------|----------|----------------------|---------|-----------------|---------|
| Ebina et al 2020<sup>26</sup> | Kansai district, Japan Registry data (2001–2019) | 3897 patients and 4415 treatment courses: ETN (856), TCZ (851), IFX (724), ABT (663), ADA (536), GOL (458), CZP (226), TOF (101) | Multicentre, retrospective ANSWER study | Assess retention rates and reasons for discontinuation for 7 bDMARDs and TOF in bDMARD-naive and bDMARD-switched RA patients | NA | Significant differences between agents for drug retention in bDMARD-naive and bDMARD-switched patients: ineffectiveness, 22.8%; ADRs, 13.2%; non-ADR reasons, 7.7%; remission, 2.3%; all-causality AEs, 38.5% |
| Croiteru et al 2019<sup>27</sup> | Israeli RA registry (January 2010–February 2019) | 864 treatment courses: TCZ (297), ETN (242), ABT (115), TOF (111), GOL (99) | Prospective cohort study | Real-life retention of TOF in RA | TCZ had longer drug persistence compared with TOF, ETN, ABT & GOL | TOF median drug persistence was 15.8 months (95% CI: 8.6–23.1) and non-inferior to ETN (26.4 months, 95% CI: 5.9–46.9; p=0.426), ABT (20.3 months, 95% CI: 9.8–30.9; p=0.157), and GOL (15.1 months, 95% CI: 5.9–24.3; p=0.698) |
| Mueller et al 2019<sup>28</sup> | Swiss St. Gallen & Aarau Cohorts (January 2015 – April 2017) | 144 | Retrospective cohort study | Assess the clinical tolerability and effectiveness of TOF | Initiated on TOF 5 mg BID | Mean DAS28 decreased significantly from baseline to 3.13 at 360 days. Discontinuation rate during follow-up (mean 1.22 years), 38.2%; due to insufficient response (14.6%), AEs (23.6%) |
| Finckh et al 2020<sup>29</sup> | Swiss Clinical Quality Management in Rheumatoid Arthritis (SCQM-RA) Registry | 2600 patients and 4023 treatment courses: TNFi (1862); bDMARDs-OMA (1355); TOF (806) initiators | Observational nested cohort study | Overall drug retention | TOF ≤5 mg bd (96.6%); >5–10 mg BID (3.4%); 47% monotherapy; 53% combination with csDMARDs | TOF drug maintenance comparable with non-TNFi bDMARDs and significantly higher than TNFi | Overall drug maintenance: HR=1.29 (95% CI: 1.14–1.47) for TOF vs TNFi; HR=1.09 (95% CI: 0.96–1.24) for TOF vs non-TNFi bDMARDs |
| Zengin et al 2018<sup>30</sup> | Turkish nationwide TURKBIO registry | 180 | Cohort study in patients with RA | Investigate the persistence, effectiveness and safety of TOF in RA patients | NA | VAS pain scores, DAS28, HAQ & CRP significantly reduced from baseline to week 60 | TOF persistence rates of 75% at 48 weeks and 48% at 137 weeks. Main reasons for drug discontinuation: ineffectiveness (6.3%), AEs (23%) |

(Continued)
## Table 1 (Continued).

| Study | Data Source | n | Design and Patients | Objectives | Tofacitinib Treatment | Main Findings | Treatment Persistence, Discontinuation and Adherence |
|-------|-------------|---|---------------------|------------|-----------------------|---------------|-------------------------------------------------------|
| Bilgin et al 2020<sup>11</sup> | Turkish single centre: Hacettepe University biological database (HUBIO) | 31 | Retrospective longitudinal study | Assess real-life effectiveness, retention rate and safety in RA patients receiving TOF | At last visit: monotherapy (± glucocorticoid), 16.6%; combination with ≥1 csDMARD, 83.4% | TOF effective as monotherapy or in combination with csDMARDs | 1-year crude retention rate was 64%. Median duration of drug retention was 24.8 months |
| Bird et al 2019; Bird et al 2020<sup>12</sup> | Australian Optimizing Patient outcomes in Australian Rheumatology (OPAL) dataset (March 2015 – September 2018) | 1950 patients: propensity score-matched for treatment initiated with: bDMARDs (n=1300); TOF (n=650). | Retrospective, non-interventional cohort study | Evaluate treatment effectiveness and persistence | TOF monotherapy, 43.4% | TOF and bDMARDs had similar treatment effectiveness and persistence. | Median treatment persistence: TOF, 34.2 months (95% CI: 32.2–not reached); bDMARDs, 33.8 months (95% CI: 28.8–40.4) |

Abbreviations: ABT, abatacept; ADA, adalimumab; AE, adverse event; bDMARDs, biologic DMARDs; BID, twice daily; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; CZP, certolizumab pegol; CI, confidence interval; csDMARDs, conventional synthetic DMARDs; DAS, disease activity score; DAS28-ESR, disease activity score in 28 joints using erythrocyte sedimentation rate; ETN, etanercept; GLM, golimumab; HAQ, Health Assessment Questionnaire; IFX, infliximab; HR, hazard ratio; LDA, low disease activity; MCID, minimum clinically important difference; MPR, medication possession ratio; MTX, methotrexate; NA, not applicable; OR, odds ratio; QD, once daily; PDC, proportion of days covered; RTX, rituximab; SD, standard deviation; SDAI, Simplified Disease Activity Index; TCZ, tocilizumab; TNFi, tumour necrosis factor inhibitor; TOF, tofacitinib.
tofacitinib MR compared with the IR formulation. Duration of treatment was comparable for both formulations.

A Canadian study of IBM MarketScan Research databases with data from the US found that new tofacitinib users (n = 1031) had shorter medication persistence compared to new bDMARD patients (n = 17,803). Median persistence was 0.81 vs 1.02 years, respectively, and the adjusted hazard ratio (HR) for discontinuation of tofacitinib compared with bDMARDs was 1.14 (95% CI: 1.05–1.25). However, patients who switched from a bDMARD to tofacitinib had longer persistence than those who switched from one bDMARD to another agent: adjusted HR for discontinuation was 0.90 (95% CI: 0.83–0.97).

A Canadian study from the Ontario Best Practices Research Initiative (OBRI) in patients initiating tofacitinib (n = 208) or TNFi (n = 357), reported discontinuation rates of 36% and 29%, respectively, during a mean follow-up of 17.3 months. Discontinuation rates in patients receiving tofacitinib monotherapy or in combination with MTX were similar.

Data from the Canadian eXel programme reported a discontinuation rate for tofacitinib initiators (n = 3678) of 33.3%, which was due to ineffectiveness in 35.7% of cases, adverse events (AEs) in 26.9%, and patient decision to try another therapy in 12.0% of cases. Temporary cessation was observed in 7.7% of patients. Persistence rates at 1 and 2 years were 62.7% and 49.6%, respectively (defined as percentage of patients remaining on tofacitinib after receiving ≤1 dose). Median drug survival in bDMARD-naïve, post-1 bDMARD, post-2 bDMARD and post≥3 bDMARD patients, was >730, 613, 667 and 592 days, respectively. An increased likelihood of tofacitinib persistence was associated with bDMARD-naïvity (vs bDMARD-experienced; p < 0.001), increased aged (≥56 vs ≤45 years; p < 0.05) and time since diagnosis of 15–19 years (vs ≤5 years; p < 0.01).

A single centre Japanese study of RA patients (n = 100) found that after year 1 of tofacitinib treatment, 53% achieved remission and a further 15% had low disease activity (CDAI < 2.8 and ≤ 10). The 1-year discontinuation rate was 32% (ineffectiveness 24%, AEs 4% and patient preference 4%). Interim analysis of post-marketing surveillance of tofacitinib in Japan reported that during the first 6 months of study, 22.7% of all patients (n = 3929) discontinued treatment mainly due to AEs (8.9%) and lack of efficacy (8.5%).

The Japanese ANSWER retrospective study of registry data compared drug retention for 7 bDMARDs and tofacitinib in biologic-naïve and biologic-experienced RA patients. For tofacitinib, data were available for 101 patients who were switched from a bDMARD. Drug discontinuation rates due to lack of effectiveness differed significantly between the 8 agents in bDMARD-switched patients (p < 0.001), ranging from relatively low values for tocilizumab (18.9%) and tofacitinib (22.8%) to 46.1% for certolizumab pegol. Drug discontinuation rates due to remission were comparable and ranged from 1.1% for certolizumab pegol to 3.3% for golimumab, and with 2.3% for tofacitinib.

Analysis of Israeli RA registry data on 864 treatment courses compared persistence for four bDMARDs and tofacitinib. Median drug persistence for tofacitinib was 15.8 months (95% CI: 8.6–23.1) and was non-inferior to etanercept (26.4 months, 95% CI: 5.9–46.9; p = 0.426), abatacept (20.3 months, 95% CI: 9.8–30.9; p = 0.157) and golimumab (15.1 months, 95% CI: 5.9–24.3; p = 0.698). Compared with tofacitinib, etanercept, abatacept and golimumab, tocilizumab had a significantly higher retention rate (HR for drug survival vs tofacitinib was 1.92, 95% CI: 1.33–2.76), but tofacitinib was mostly prescribed as third or later line of therapy (64%).

A Swiss retrospective study of the St. Gallen and Aarau Cohorts assessed tolerability and effectiveness in patients initiated on tofacitinib (n = 144). Tofacitinib significantly reduced mean DAS28 from 4.4 at baseline to 3.13 at 360 days; 53% of patients achieved LDA and 48% DAS28-defined remission. The rates of LDA and remission for tofacitinib were higher in biologic-naïve patients compared to those who had previous biologic exposure: 100% of biologic-naïve patients achieved LDA and 83.3% achieved remission, compared with 53.3% and 44.9% of patients pre-exposed to biologics. The discontinuation rate during a mean of 1.22 years follow-up was 38.2% which was attributable to AEs (23.6%) and insufficient response (14.6%).

Analysis of the Swiss Clinical Quality Management in Rheumatoid Arthritis (SCQM-RA) Registry found that drug maintenance in tofacitinib initiators (n = 806) was significantly higher than TNFi initiators (n = 1862) and comparable with non-TNFi bDMARDs (eg, rituximab, tocilizumab, abatacept) initiators (n = 1355). Median (IQR) drug maintenance was 25 months (19–30) for tofacitinib, 19 months (17–22) for non-TNFi bDMARDs and 17 months (15–18) for TNFi. The adjusted HR for drug discontinuation with TNFi compared with tofacitinib was 1.29 (95% CI: 1.14–1.47) and was 1.09 (95% CI: 0.96–
1.24) for both non-TNFi bDMARDs and tofacitinib. Discontinuation was most commonly due to ineffectiveness with lower rates for tofacitinib (46%) compared with non-TNFi bDMARDs (50%) and TNFi (57%).

A retrospective analysis of RA patients (n = 180) in the Turkish nationwide TURKBIO registry showed that tofacitinib significantly reduced VAS pain scores, DAS28, HAQ and C-reactive protein (CRP) from baseline to week 60. Tofacitinib persistence rates were 75% at 48 weeks and 48% at 137 weeks. The main reasons for tofacitinib discontinuation were ineffectiveness (63%) and AEs (23%). In a Turkish single centre study (n = 204), tofacitinib reduced mean ± SD DAS28-ESR levels from 4.7 ± 1.4 at baseline to 3.6 ± 1.5 at last visit (median 10.2 months); tofacitinib had a 1-year crude retention rate of 64% and a median duration of drug retention of 24.8 months.

Analysis of the Australian Optimizing Patient outcomes in Australian RheumatoLogy (OPAL) dataset used propensity score matching at a ratio of 1:2 to compare with tofacitinib (n = 650) and bDMARDs (n = 1300). Similar DAS remission rates at 18 months were reported for tofacitinib (57.8%) and bDMARDs (52.4%) and the proportion of patients achieving CDAI or SDAI remission was similar with respective rates of 30.9% and 30.5% for tofacitinib, and 29.2% and 29.0% for bDMARDs. Median treatment persistence was similar for tofacitinib (34.2 months; 95% CI: 32.2–not reached) and bDMARDs (33.8 months; 95% CI: 28.8–40.4).

Safety
Results from real-world studies on the safety and tolerability of tofacitinib are summarised in Table 2. A prospective, observational study of US Corrona RA registry data evaluated 5-year AE incidence rates in propensity score trimmed tofacitinib (n = 1117) and bDMARD (n = 5542) initiators. The most common AEs in an interim analysis (first 6-month observation period) of a 3-year study post-marketing surveillance of tofacitinib (n = 3929) in Japan were herpes zoster (3.7%) and abnormal hepatic function (1.8%). Serious AEs were reported in 287 patients (7.3%), commonly herpes zoster (0.6%) and pneumonia/bacterial pneumonia (0.8%).

A retrospective study of Swiss Cohorts (n = 144) found a discontinuation rate due to AEs of 23.6% which was comparable to that reported in the ORAL Sequel LTE study (25%). Gastrointestinal symptoms (12.5%) were the main reason for stopping treatment in the Swiss Cohorts. A retrospective Turkish single centre study found that tofacitinib was well tolerated and had a discontinuation rate due to AEs of 15.0%, most commonly due to allergic skin reactions (2.4%). The most common infectious and laboratory AEs were herpes zoster (3.9 per 100 patient-years) and ALT elevation (9.7 per 100 patient-years), respectively.

Thrombosis/Cardiovascular Disease (CVD)
Retrospective analysis of the US FORWARD database spanning 20 years, which included 17,363 RA patients, compared the CVD risk with biologics and tofacitinib to csDMARDs. The study found a significant reduction in CVD risk with TNFi and abatacept, a non-significant reduction with tofacitinib and a significant increase with glucocorticoids. Adjusted HRs for CVD vs csDMARDs were: TNFi, 0.79 (95% CI: 0.69–0.92), abatacept, 0.53 (95% CI: 0.30–0.92); tofacitinib, 0.33 (95% CI: 0.05–2.38); rituximab, 0.78 (95% CI: 0.41–1.47); tocilizumab, 1.00 (95% CI: 0.44–2.27); anakinra, 0.87 (95% CI: 0.32–2.33); and glucocorticoids, 1.15 (95% CI: 1.11–1.20).

In the US Corrona RA registry, incidence rates of MACE and VTE were comparable for tofacitinib and bDMARD initiators. This prospective, observational, 5-year analysis examined data from 1544 initiators of tofacitinib (2138 patient-years) and 7083 bDMARD (9905 patient-years) initiators. The adjusted HR for MACE for both cohorts was 0.60 (95% CI: 0.30–1.18). Rates of VTE were also similar between tofacitinib and bDMARDs.

Analysis of US MarketScan claims databases found comparable risks for VTE in patients initiating treatment with tofacitinib (n = 2155) and adalimumab (n = 6022). After a median follow-up of 0.5 years, the VTE incidence rate for tofacitinib was 1.31 per 100 patient-years (95% CI: 0.80–2.03) and for adalimumab was 0.83 per 100 patient-years (95% CI: 0.60–1.14). Analysis of US Truven MarketScan (n = 34,074) and Medicare claims (n = 17,086) databases found no significant difference in the risk of VTE between tofacitinib-treated and TNFi-treated patients. The crude incidence rate of VTE in the Truven database for tofacitinib was 0.60 per 100 person-years (95% CI: 0.26–1.19) and for TNFi was 0.34 (95% CI: 0.27–0.41); in the Medicare database it was 1.12 (95% CI: 0.45–2.31) and 0.92 (95% CI: 0.76–1.11), respectively.
| Study                        | Data Source                                      | N                          | Design and Patients                  | Objectives                                                                 | Main Findings                                                                                                                                                                                                 | Discontinuation Rate due to AEs                                                                 |
|-----------------------------|--------------------------------------------------|-----------------------------|--------------------------------------|------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Kremer et al 2019<sup>13</sup> | US Corrona RA registry                           | 1544 TOF & 7083 bDMARD starters. After propensity score-matching: 1117 TOF & 5542 bDMARD starters | Prospective, observational 5-year study                                        | Evaluate 5-year AE incidence rates (IRs) in new starters of TOF vs bDMARDs                                                                                                                                      | Patients starting TOF or bDMARDs had similar MACE, SIE, and VTE rates. TOF starters had higher HZ IRs vs bDMARD starters.                                                                 | NA                                                                                                                                                                                                 |
| Tamura et al 2018<sup>14</sup> | Post-marketing surveillance in Japan              | 3929                        | Post-marketing interim analysis (first 6-month observation period) of 3-year follow-up | Rates of SAEs, malignancies, and deaths in Japanese RA patients receiving TOF | SAEs in 7.3% of patients: commonly herpes zoster (0.6%) and pneumonia/bacterial pneumonia (0.8%). See Malignancy section below for cancer rates                                                                 | NA                                                                                                                                                                                                 |
| Mueller et al 2019<sup>15</sup> | Swiss St. Gallen & Aarau Cohorts (January 2015 – April 2017) | 144                         | Retrospective                        | Assess the clinical tolerability and effectiveness of TOF                    | TOF was safe with an AE discontinuation rate comparable with LTE studies                                                                                                                                         | AE discontinuation rate 23.6%. GI symptoms (12.5%), infection (3.5%), myalgia (14%), headache (14%), cough, blue finger syndrome, intolerance, heartburn, psoriasis, and increased liver enzymes (0.7%) |
| Bilgin et al 2020<sup>16</sup> | Turkish single centre: Hacettepe University biological HUR-BIO database | Retention and safety (n=247) | Retrospective longitudinal study     | Assess real-life effectiveness, retention rate and safety in RA patients receiving TOF | TOF was well-tolerated. Most common infectious AE was herpes zoster (3.9 per 100 patient-years) and laboratory AE was ALT elevation (9.7 per 100 patient-years)                                                                 | TOF discontinuation rate due to AEs. 15.0%, most commonly allergic skin reaction (2.4%)                                                                                                     |
| Cardiovascular disease (CVD) |                                                   |                             |                                      |                                                                              |                                                                                                                                                                                                             |                                                                                                                                                                                                 |
| Ozen et al 2018<sup>17</sup>  | US FORWARD database - The National Databank for Rheumatic Diseases, (1998–2017) | 17,363                      | Retrospective                        | Compare effects of bDMARDs and TOF vs csDMARDs on incident CVD in RA patients | Significant CVD risk reduction with TNFi and ABT compared with csDMARDs. Adjusted HR (95% CI) for CVD vs csDMARDs: TNFi, 0.79 (0.69–0.92), ABT, 0.53 (0.30–0.92); TOF, 0.33 (0.05–2.38); RTX, 0.78 (0.41–1.47); TCZ, 1.00 (0.44–2.27); anakinra, 0.87 (0.32–2.33). | (Continued)                                                                                                                                                                                                 |

(Continued)
| Study          | Data Source                                                                 | N                | Design and Patients                          | Objectives                                                                 | Main Findings                                                                 | Discontinuation Rate Due to AEs |
|---------------|------------------------------------------------------------------------------|------------------|----------------------------------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------|---------------------------------|
| Yun et al 2018 | US Marketscan claims databases (2010–2015)                                  | TOF (n=2155) and adalimumab (n=6022) initiators | Retrospective cohort study                  | Evaluate risk of VTE (composite of PE or DVT) in RA patients initiating TOF or adalimumab | Comparable risk for VTE in patients treated with TOF or adalimumab.             | VTE incidence rates: TOF, 1.31 per 100 patient-years (95% CI: 0.80–2.03); adalimumab, 0.83 (95% CI: 0.60–1.14) |
| Desai et al 2019 | US Truven MarketScan database (2012–2016), Medicare claims database (2012–2015) | SI,160: 34,074 (Truven), 17,086 (Medicare) | Retrospective cohort study                  | Evaluate risk of VTE in RA patients receiving TOF versus TNF inhibitors      | No significant difference in risk of VTE between TOF- and TNFi-treated patients. |                                                |
| Mease et al 2020 | US Corrona registry, IBM MarketScan research databases, US FDA Adverse Event Reporting System (FAERS) database. | Corrona RA registry: bDMARD initiators (n=5159), TOF initiators (n=1130); MarketScan database for RA: all bDMARD initiators (n=47,496), TOF (n=5521); TOF FAERS data: 1210 unique reports | Retrospective real-world database analysis | Venous and arterial thromboembolic events in TOF RA, PsO & PsA real-world data | VTE and ATE incidence rates comparable for bDMARD and TOF initiators. Corrona RA registry: incidence rates (95% CI) for VTE: bDMARD initiators 0.32 (0.20–0.47), TOF initiators 0.18 (0.04–0.51) |
| Machado et al 2018 | US MarketScan® databases (01/01/11–31/12/14)                              | 21,832 patients treated with: TOF (164); non-TNF biologics (2902); TNFi therapy (13,367); other DMARDs (5399) | Retrospective cohort study of adults with RA previously treated with MTX | Study of effectiveness and safety of MTX-exposed patients with RA, newly prescribed with: TOF, other DMARDs (not MTX), or biologics | Similar hospitalised infection rates for TOF ± DMARDs, DMARDs and TNFi ± DMARDs. Rates of serious infections: TOF ± DMARDs, 3.67 per 100 patient-years (95% CI: 2.21–5.75); DMARDs, 2.01 (95% CI: 1.65–2.42); TNFi ± DMARDs, 2.16 (95% CI: 1.98–2.36) | NA                              |
| Study                | Database Details                                                                 | Participants | Study Type          | Key Findings                                                                                          |
|---------------------|----------------------------------------------------------------------------------|--------------|---------------------|------------------------------------------------------------------------------------------------------|
| Curtis et al 2019   | US MarketScan and Medicare databases (2011–2016)                                 | 8030 new TOF users | Retrospective cohort study | Evaluated herpes zoster risk in TOF users with / without MTX & glucocorticoids                        |
| Pawar et al 2020    | US Medicare (2012–2015), Optum Clinformatics (2012–2018) and IBM MarketScan (2012–2017) databases | 130,718       | Retrospective multi-database cohort study | Compared risk of serious infection in RA patients initiating TOF or other bDMARDs                    |
| Winthrop et al 2021 | US Corrona RA registry                                                            | Registry data set (n = 10,357): TOF, (n=1999), bDMARD (n=8358). | Retrospective cohort study | Assessed age-based (<65 vs ≥65 years) SIE risk in RA patients receiving TOF or bDMARD initiators     |
| Tamura et al 2018   | Post-Marketing Surveillance in Japan                                               | 3929          | Interim analysis (first 6-month observation period) of 3 year surveillance | Incidence of SIEs in Japanese RA patients treated with TOF                                           |
| Bilgin et al 2020   | HURBIO Registry, Turkey                                                            | 204           | Retrospective longitudinal study | Assessed the real-life incidence of herpes zoster in RA patients receiving TOF                      |

Serious infection risk with TOF was significantly higher than etanercept, significantly lower than infliximab and non-significantly higher than ABT, GOL, and TCZ. TOF was associated with a 2-fold higher risk of herpes zoster vs all bDMARDs.

SIE incidence was higher in older vs younger patients in both TOF initiators and bDMARD initiators. SIE incidence similar between TOF and bDMARD initiators for both age groups.

Incidence rates (95% CI) of SIEs in the Corrona RA registry: aged <65 years: TOF initiators, 1.89 (1.34–2.59); bDMARD initiators, 2.20 (1.88–2.56)  
Aged ≥65 years: TOF initiators, 5.32 (4.02–6.91); bDMARD initiators 4.20 (3.62–4.86)

At month 6, SIEs in 130 (3.3%) patients: herpes zoster (n=24; 0.6%), pneumonia (n=23; 0.6%), Pneumocystis jiroveci pneumonia (n=15; 0.4%), bacterial pneumonia (n=10; 0.3%).

Herpes zoster incidence rate, 3.9 (95% CI: 2.3–8.5) per 100 patient-years

(Continued)
| Study | Data Source | N | Design and Patients | Objectives | Main Findings | Discontinuation Rate Due to AEs |
|-------|-------------|---|---------------------|------------|---------------|-------------------------------|
| **Malignancy** | | | | | | |
| Tamura et al 2018 | Post-marketing surveillance in Japan | 3929 | Post-marketing interim analysis (first 6-month observation period) of 3-year follow-up | Rates of SAEs, malignancies, and deaths in Japanese RA patients receiving TOF. | All-causality malignancy in 0.6% (n=25); 0.3% (n=12) reported to be treatment-related. | |
| Kremer et al 2019 | US Corrona RA registry (Nov 6, 2012 – July 31, 2018) | TOF (n=1999) and bDMARD (n=6354) initiators | Patients propensity score-matched for total cancer (excluding NMSC), NMSC, and death | Compared 5-year incidence rates for SAEs & AEs of interest in patients starting TOF vs bDMARDs | RA patients initiating TOF or bDMARDs had similar rates of total cancer excluding NMSC, NMSC, and death | |
| Xie et al 2020 | Meta-analysis of 10 observational studies | 42,168 patients and >87,622 patient-years of exposure to non-TNFi biologics; 2221 patients with >4506 patient-years of exposure to TOF | Meta-analysis of real-world data | Assessed risk of developing cancer in RA patients exposed to non-TNFi biologics or TOF therapy | No increased risk of developing cancer overall or in specific cancer types in RA patients receiving TOF compared with csDMARDs or TNFi | |

**Abbreviations:** ADRs, adverse drug reactions; AEs, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ATE, arterial thromboembolism; bDMARDs, biologic DMARDs; CI, confidence interval; CRP, C-Reactive Protein; csDMARDs, conventional synthetic DMARDs; DMARDs, disease-modifying anti-rheumatic drug; DVT, deep vein thrombosis; GI, gastrointestinal; HR, hazard ratio; LDA, low disease activity; MACE, major adverse cardiovascular events; MTX, methotrexate; NA, not available; NMSC, non-melanoma skin cancer; PE, pulmonary embolism; PsA, psoriatic arthritis; PsO, psoriasis; RR, relative risk; SAE, serious adverse event; SIE, serious infection event; TNFi, tumour necrosis factor inhibitor; TOF, tofacitinib; VTE, venous thromboembolism.
Mease et al 2020 reported observational data from the US Corrona registries (including cardiovascular risk factor stratification), IBM MarketScan research databases and the US FDA Adverse Event Reporting System (FAERS) database as well as results from separate RA, psoriasis (PsO) and psoriatic arthritis (PsA) development programmes for tocafitinib 5 mg vs 10 mg BID. Incidence rates of deep vein thrombosis (DVT), pulmonary embolism (PE) and arterial thromboembolism (ATE) in the tocafitinib RA, PsO and PsA programmes were similar across tocafitinib doses, and were generally consistent with the real-world data. In the Corrona RA registry, the VTE incidence rate for bDMARD initiators was 0.32 per 100 patient-years’ exposure (95% CI: 0.20–0.47) and 0.18 (95% CI: 0.04–0.51) for tocafitinib initiators. In the MarketScan databases for RA, incidence rates of VTE were 0.94 (95% CI: 0.85–1.03) and 1.05 (95% CI: 0.78–1.39), respectively. Respective incidence rates for ATE were 0.04 (95% CI: 0.03–0.07) and 0.04 (95% CI: 0.00–0.17), respectively.

**Infections**

Retrospective analysis of US MarketScan databases of adults with RA previously treated with MTX (n = 21,832) found similar hospitalised infection rates for tocafitinib ± DMARDs, DMARDs and TNFi ± DMARDs. Rates of serious infections were: tocafitinib ± DMARDs, 3.67 per 100 patient-years (95% CI: 2.21–5.75); DMARDs, 2.01 (95% CI: 1.65–2.42); and TNFi ± DMARDs, 2.16 (95% CI: 1.98–2.36).

Retrospective analysis of US MarketScan and Medicare databases of new users of tocafitinib (n = 8030) with or without MTX and glucocorticoids estimated the herpes zoster infection rate as approximately 4% per year.

Analysis of multiple databases in the US reported that serious infection risk with tocafitinib was significantly higher than with etanercept, significantly lower than with infliximab, non-significantly higher than with abatacept, golimumab and tocilizumab, and similar to adalimumab and certolizumab. Adjusted HRs for serious infection for tocafitinib vs bDMARDs were: vs etanercept, 1.41 (95% CI 1.15–1.73); vs infliximab, 0.81 (95% CI: 0.65–1.00) vs abatacept, 1.20 (95% CI: 0.97–1.49); vs golimumab, 1.23 (95% CI: 0.94–1.62); tocilizumab, 1.17 (95% CI: 0.89–1.53); vs adalimumab, 1.06 (0.87–1.30); vs certolizumab pegol, 1.02 (95% CI: 0.80–1.29).

In the US Corrona RA registry, the adjusted HR for SIEs was 0.99 (95% CI: 0.72–1.36), and tocafitinib initiators had higher rates of herpes zoster compared with bDMARD initiators for a significantly increased adjusted HR (2.12; 95% CI: 1.22–3.66). All herpes zoster events with tocafitinib were non-serious. When stratified by age (<65 vs ≥65 years), the incidence of serious infections with tocafitinib vs bDMARDs was higher in older patients for both tocafitinib initiators and bDMARD initiators and similar between tocafitinib and bDMARD initiators for both age groups.

All-case post-marketing surveillance in Japanese patients with RA treated with tocafitinib reported that 6-month serious infection events occurred in 130 (3.3%) patients, most commonly herpes zoster (0.6%) and pneumonia (0.6%).

Assessment of the risk for herpes zoster in tocafitinib-treated RA patients, with or without concomitant methotrexate and glucocorticoids, reported an infection rate of approximately 4% per year.

**Malignancy**

The prospective, observational, 5-year analysis of the US Corrona RA registry examined data from 1999 patients initiating tocafitinib (4505.62 patient-years) and 6354 initiating a bDMARD (16,670.84 patient-years). In the entire population, HRs were: for total cancer (excluding NMSC), 1.04 (95% CI: 0.68–1.61); NMSC, 1.02 (95% CI: 0.69–1.50); and death, 1.0 (95% CI: 0.62–1.63). Similar rates of all cancers (excluding NMSC), NMSC and death were seen for tocafitinib and bDMARDs.

Interim (6-month) post-marketing surveillance of malignancy in Japanese RA patients treated with tocafitinib reported all-cause malignancy in 25 patients (0.6%), of which 12 were considered to be treatment-related. A total of 21 deaths (0.5%) occurred during the 6-month period, most commonly due to infection (n = 6; 0.15%) and malignancy (n = 5; 0.13%). Over 36 months, malignancy was reported in 61 patients (4874 patient-years) with a cumulative incidence rate of 1.25/100 patient-years. Rates of malignancies and death were comparable with those in the tocafitinib RA clinical programme and no new or unexpected safety risks were identified.

A meta-analysis of observational studies assessed the risk of malignancy with non-TNFi biologic or tocafitinib therapy in RA. The analysis, including 10 studies and involving 42,168 patients and >87,622 patient-years of exposure to non-TNFi biologics, included 2221 patients with >4506 patient-years of exposure to tocafitinib. There was no increased risk of developing cancer overall or in
specific cancer types in RA patients receiving tofacitinib compared with those receiving csDMARDs or TNFi.

Discussion

Drug retention rates may differ markedly between different bDMARDs. Several factors affecting bDMARD drug retention rates have been reported, although some appear to be drug- or drug class-specific. For tofacitinib, bDMARD-naïvity (compared with prior bDMARD experience), older age (>56 vs ≤45 years) and longer time since diagnosis (15–19 vs <5 years) significantly increased the likelihood of drug retention in a study from Canada, but these findings wait further confirmation. Future real-world studies may delineate other predictors of tofacitinib drug retention.

Discontinuation rates due to ineffectiveness were slightly lower with tofacitinib (46%) than non-TNFi bDMARDs (50%) and TNFi (57%), but rates due to intolerance or AEs were comparatively higher with tofacitinib: 30% versus 22% and 19%, respectively. In these analyses of Swiss Registry data, median drug maintenance was longer for tofacitinib (25 months), than non-TNFi bDMARDs (19 months) and TNFi (17 months). In contrast, a retrospective, non-interventional cohort analysis of the Australian OPAL dataset (derived from 42 rheumatology clinics in Australia, collecting information from individual clinicians’ servers during routine clinical consultations) reported similar median treatment persistence of approximately 34 months for tofacitinib compared with bDMARDs. A previous review of real-world studies (up to mid-2018) found that treatment persistence and adherence to tofacitinib was good overall and similar to those seen for bDMARDs. RA patients initiating tofacitinib usually had longer disease duration and had been exposed to longer bDMARDs than patients initiating a bDMARD. Real-world data demonstrate the value of monotherapy with tofacitinib, showing the drug retention rate is not affected when in association with MTX, differently than bDMARDs, and the effectiveness of tofacitinib as monotherapy appears similar to tofacitinib in combination therapy, in contrast to anti-TNF agents.

There is growing evidence of the safety of JAK inhibitors in patients with RA. Evaluation of the risks of relatively rare serious AEs such as VTE, gastrointestinal perforation and interstitial lung disease in clinical practice requires the accumulation of cases with these events. Continuous pharmacovigilance activity is essential to establish the safety of JAK inhibitors in patients with RA and other rheumatic diseases.

Patients with RA have increased risk of CVD. Observational studies suggest that in the general population and non-RA controls, there are 0.1–0.4 thromboembolic events per 100 patient-years. In RA, thromboembolic risks increase to 0.3–0.7 per 100 patient-years. Interestingly, a recent meta-analysis of patients with immune-mediated inflammatory diseases (n = 13,611) enrolled in RCTs (n = 29) found that tofacitinib had analogous rates of all cardiovascular events (odds ratio [OR] = 1.07, 95% CI: 0.49–2.34), MACE (OR = 1.54, 95% CI: 0.42–5.59) and all-cause mortality (OR = 1.13, 95% CI: 0.26–4.95) compared with placebo, but a decreased rate of VTEs (OR = 0.03, 95% CI: 0.00–0.21). Similarly, a meta-analysis of patients with immune-mediated inflammatory diseases enrolled in RCTs (n = 42) reported no increased risk of VTE for JAK inhibitors as a group (6542 patient exposure years) compared with placebo (1578 patient exposure years). Data pooled from six phase 3 and two long-term extension studies of tofacitinib in RA patients over 7 years, identified 52 MACE occurring in 4076 patients during 12,873 patient-years of exposure for an incidence rate of 0.4 per 100 patient-years. Additionally, a systematic literature review on 33 clinical trials, 39 prospective and 18 retrospective real-world studies, concluded that there were no indications of a significant increase in adverse cardiovascular events for bDMARDs and tofacitinib in patients with rheumatic diseases.

Importantly, data from a recently completed large randomized prospective post-authorization safety study comparing tofacitinib with anti-TNF therapy in patients with RA who were aged ≥50 years and had ≥1 additional CV risk factor showed an increased rate for tofacitinib relative to anti-TNF therapy regarding venous thromboembolic events (VTE) and major adverse cardiovascular events. Given that the underlying mechanism(s) for these adverse events remain unknown, the effect of JAK inhibitors on CVD risk requires further research.

The utility of real-world evidence for informing healthcare policymakers when making appropriate decisions about treatment pathways has been recognised. This review of tofacitinib considering recent real-world evidence provides an update from a previous review which included studies up to mid-2018. These retrospective and prospective observational studies have demonstrated the effectiveness of tofacitinib and reinforce data from the pivotal clinical trial programme. Treatment persistence was generally comparable to that of bDMARDs, and the
safety findings in these observational studies were consistent with the known safety profile of the approved dose of 5 mg BID.

Acknowledgments

Medical writing support was provided by Robert A. Furlong PhD and David P. Figgitt PhD, ISMPP CMPPTM, on behalf of Content Ed Net Spa. This support was funded by Pfizer Italy.

Funding

Writing support was funded by Pfizer Italy.

Disclosure

Roberto Caporali received an honorarium from Pfizer in connection with the development of this manuscript. Roberto Caporali reports personal fees from Abbvie, Roche, Celltrion, BMS, Amgen, Lilly, Galapagos, Sanofi, and UCB, during the conduct of the study. Ilaria Bertoldi is a Pfizer employee.

References

1. Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–699. doi:10.1136/annrheumdis-2019-216655
2. Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34:318–328.
3. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16:843–862. doi:10.1038/nrd.2017.201
4. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451–460. doi:10.1016/S0140-6736(12)61424-X
5. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507. doi:10.1056/NEJMoa1109071
6. Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390:457–468. doi:10.1016/S0140-6736(17)31618-5
7. Kremer J, Li ZG, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159:253–261. doi:10.7326/0003-4819-159-4-201308200-00006
8. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377–2386. doi:10.1056/NEJMoa1310476
9. Van Der Heijde D, Strand V, Tanaka Y, et al. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty-four-month, phase III study. Arthritis Rheumatol. 2019;71:878–891. doi:10.1002/art.40803
10. Van Der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomised radiographic study. Arthritis Rheumatol. 2013;65:559–570. doi:10.1002/art.37816
11. Van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–519. doi:10.1056/NEJMoa1112072
12. Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Rheum. Ther. 2019;21:89. doi:10.1186/s13075-019-1866-2
13. Barnish MS, Turner S. The value of pragmatic and observational studies in health care and public health. Pragmat Obs Res. 2017;8:49–55. doi:10.2147/POR.S137701
14. Bartlett VL, Drhuva SS, Shah ND, Ryan P, Ross JS. Feasibility of using real-world data to replicate clinical trial evidence. JAMA Netw. Open. 2019;2:e1912869. doi:10.1001/jamanetworkopen.2019,12869
15. Monti S, Grosso V, Todeserti M, Caporali R. Randomized controlled trials and real-world data: differences and similarities to untangle literature data. Rheumatology (Oxford). 2018;57:vii54–vii8. doi:10.1093/rheumatology/key109
16. Caporali R, Zavaglia D. Real-world experience with tofacitinib for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2019;37:485–495.
17. Machado MAA, Moura CS, Guerra SF, Curtis JR, Abrahamowicz M, Bernatsky S. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. Arthritis Res Ther. 2018;20:60. doi:10.1186/s13075-018-1539-6
18. Reed GW, Gerber RA, Shan Y, et al. Real-world comparative effectiveness of tofacitinib and tumor necrosis factor inhibitors as monotherapy and combination therapy for treatment of rheumatoid arthritis. Rheumatol Ther. 2019;6(4):573–586. doi:10.1007/s40744-019-00177-4
19. Harnett J, Smith T, Woolcott J, Gruben D, Murray C. Impact of TNF inhibitor cycling with adalimumab and etanercept vs switching to tofacitinib [abstract number: 1426]. Arthritis Rheumatol. 2019;71(suppl 10). Available from: https://acrabstracts.org/abstract/impact-of-tnf-inhibitor-cycling-with-adalimumab-and-etanercept-vs-switching-to-tofacitinib/
20. Cohen SB, Greenberg JD, Harnett J, et al. Real-world evidence to contextualize clinical trial results and inform regulatory decisions: tofacitinib modified-release once-daily vs immediate-release twice-daily for rheumatoid arthritis. Adv Ther. 2020;38(1):226–248. doi:10.1007/s12325-020-01501-z
21. Fisher A, Hudson M, Platt RW, Dormuth CR; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Tofacitinib persistence in patients with rheumatoid arthritis: a retrospective cohort study. J Rheumatol. 2020;47(1):16–24. doi:10.3899/jrheum.1911252
22. Movahedi M, Cesta A, Li X, Keystone E, Bombardier C. Time to discontinuation of tofacitinib in rheumatoid arthritis patients with and without methotrexate: results from a rheumatoid arthritis cohort. Ann Rheum Dis. 2020;79(suppl 1):131. doi:10.1136/annrheumdis-2020-eular.1745
23. Pope J, Bessette L, Jones N, et al. Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 years. Rheumatology (Oxford). 2020;59:568–574. doi:10.1093/rheumatology/kez324
24. Mori S, Ueki Y. Outcomes of dose reduction, withdrawal, and restart of tofacitinib in patients with rheumatoid arthritis: a prospective observational study. Clin Rheumatol. 2019;38:3391–3400. doi:10.1007/s10067-019-04721-z
25. Tamura N, Kuvana M, Atsumi T, et al. Infection events in Japanese patients with rheumatoid arthritis treated with tofacitinib: interim all-case post-marketing surveillance [abstract number: 1516]. Arthritis Rheumatol. 2018;70(suppl 10). Available from: https://acrabstracts.org/abstract/infection-events-in-japanese-patients-with-rheumatoid-arthritis-treated-with-tofacitinib-interim-all-case-post-marketing-surveillance/.
For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.

For personal use only.
53. Yates M, Mootoo A, Adas M, et al. Venous thromboembolism risk with JAK inhibitors: a meta-analysis. *Arthritis Rheumatol*. 2020;73(5):779–788. doi:10.1002/art.41580

54. Charles-Schoeman C, Demasi R, Valdez H, et al. Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. *Arthritis Rheumatol*. 2019;71:1450–1459. doi:10.1002/art.40911

55. Nurmohamed M, Choy E, Lula S, Kola B, Demasi R, Accossato P. The impact of biologics and tofacitinib on cardiovascular risk factors and outcomes in patients with rheumatic disease: a systematic literature review. *Drug Saf*. 2018;41:473–488. doi:10.1007/s40264-017-0628-9

56. EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots. European Medicines Agency; 2021. Available from: https://www.ema.europa.eu/en/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_en.pdf. Accessed July 17, 2021.

57. Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib). US Food And Drug Administration; 2021. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/initial-safety-trial-results-find-increased-risk-serious-heart-related-problems-and-cancer-arthritis. Accessed July 17, 2021.

58. Bowrin K, Briere JB, Levy P, Millier A, Clay E, Toumi M. Cost-effectiveness analyses using real-world data: an overview of the literature. *J Med Econ*. 2019;22:545–553. doi:10.1080/13696998.2019.1588737